Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

navitoclax (ABT 263)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AbbVie

Drug class:

Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor

Related drugs:

EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2
STRN-ALK rearrangement	Mesothelioma	STRN-ALK rearrangement	Mesothelioma	ABT 263 Sensitive: D – Preclinical ABT 263 Sensitive : D	ABT 263 Sensitive: D – Preclinical ABT 263 Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	trametinib + ABT 263 Sensitive: D – Preclinical trametinib + ABT 263 Sensitive : D	trametinib + ABT 263 Sensitive: D – Preclinical trametinib + ABT 263 Sensitive : D
EGFR overexpression	Triple Negative Breast Cancer	EGFR overexpression	Triple Negative Breast Cancer	ABT 263 + ABBV-321 Sensitive: D – Preclinical ABT 263 + ABBV-321 Sensitive : D	ABT 263 + ABBV-321 Sensitive: D – Preclinical ABT 263 + ABBV-321 Sensitive : D
EGFR overexpression	Triple Negative Breast Cancer	EGFR overexpression	Triple Negative Breast Cancer	ABT 263 + ABT-414 Sensitive: D – Preclinical ABT 263 + ABT-414 Sensitive : D	ABT 263 + ABT-414 Sensitive: D – Preclinical ABT 263 + ABT-414 Sensitive : D
BCL2L2 overexpression	Diffuse Large B Cell Lymphoma	BCL2L2 overexpression	Diffuse Large B Cell Lymphoma	ABT 263 Resistant: D – Preclinical ABT 263 Resistant : D	ABT 263 Resistant: D – Preclinical ABT 263 Resistant : D
KRAS G12D	Lung Cancer	KRAS G12D	Lung Cancer	selumetinib + ABT 263 Sensitive: D – Preclinical selumetinib + ABT 263 Sensitive : D	selumetinib + ABT 263 Sensitive: D – Preclinical selumetinib + ABT 263 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	ABT 263 + AZD8055 Sensitive: D – Preclinical ABT 263 + AZD8055 Sensitive : D	ABT 263 + AZD8055 Sensitive: D – Preclinical ABT 263 + AZD8055 Sensitive : D
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	ABT 263 + AZD8055 Sensitive: D – Preclinical ABT 263 + AZD8055 Sensitive : D	ABT 263 + AZD8055 Sensitive: D – Preclinical ABT 263 + AZD8055 Sensitive : D
BCL2L1 overexpression	Pancreatic Cancer	BCL2L1 overexpression	Pancreatic Cancer	ACR-368 + ABT 263 Sensitive: D – Preclinical ACR-368 + ABT 263 Sensitive : D	ACR-368 + ABT 263 Sensitive: D – Preclinical ACR-368 + ABT 263 Sensitive : D
CHEK1 overexpression	Pancreatic Cancer	CHEK1 overexpression	Pancreatic Cancer	ACR-368 + ABT 263 Sensitive: D – Preclinical ACR-368 + ABT 263 Sensitive : D	ACR-368 + ABT 263 Sensitive: D – Preclinical ACR-368 + ABT 263 Sensitive : D
EGFR L8585R + EGFR T790M + RBM10 G840fs*7	Lung Cancer	EGFR L8585R + EGFR T790M + RBM10 G840fs*7	Lung Cancer	osimertinib + ABT 263 Sensitive: D – Preclinical osimertinib + ABT 263 Sensitive : D	osimertinib + ABT 263 Sensitive: D – Preclinical osimertinib + ABT 263 Sensitive : D
EGFR L858R + RBM10 Q255*	Lung Cancer	EGFR L858R + RBM10 Q255*	Lung Cancer	osimertinib + ABT 263 Sensitive: D – Preclinical osimertinib + ABT 263 Sensitive : D	osimertinib + ABT 263 Sensitive: D – Preclinical osimertinib + ABT 263 Sensitive : D
BCL2 overexpression	Lung Cancer	BCL2 overexpression	Lung Cancer	gefitinib + ABT 263 Sensitive: D – Preclinical gefitinib + ABT 263 Sensitive : D	gefitinib + ABT 263 Sensitive: D – Preclinical gefitinib + ABT 263 Sensitive : D
DKK3 overexpression	Glioblastoma	DKK3 overexpression	Glioblastoma	ABT 263 Sensitive: D – Preclinical ABT 263 Sensitive : D	ABT 263 Sensitive: D – Preclinical ABT 263 Sensitive : D